Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.
Sanofi Pasteur is one of four global producers of the yellow fever vaccine.
In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group, changed its name to Sanofi Pasteur. In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable. Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks will run out in June 2016.
1897: Marcel Mérieux creates the Mérieux Biological Institute in Lyon. Richard Slee creates the Pocono Biological Laboratories, in Swiftwater, Pennsylvania in the U.S.
1914: John FitzGerald creates Connaught Laboratories, part of the University of Toronto.
1968: Rhône-Poulenc acquires 51% of the capital of the Institut Mérieux.
1974: Pasteur Institute creates Pasteur Production, a subsidiary specializing in manufacturing vaccines.
1978: Connaught Laboratories in Canada acquires the vaccine manufacturing facility (Merrell-National Laboratories) at Swiftwater, Pennsylvania, U.S.
1985: Pasteur Production is acquired by the Mérieux Institute, and Pasteur Vaccins is created.
1989: The Mérieux Institute acquires the Connaught Laboratories in Canada and its subsidiaries and becomes a world leader in human biology.
1990: Creation of Pasteur Mérieux Serums & Vaccins.
1994: Pasteur Mérieux Sérums & Vaccins becomes a wholly owned subsidiary of Rhône-Poulenc.
1996: Pasteur Mérieux Connaught is the new name of Pasteur Mérieux Serums et Vaccins.
1999: Rhône-Poulenc and Hoechst unite their Life Sciences activities in a single company, which takes on the name Aventis. Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur.
2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur.
2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics.
Sanofi Pasteur
2012 net sales: €3,897 millions (+5.7% over 2011)
Staff: nearly 13,000 employees worldwide
More than 1 billion doses of vaccines produced yearly to immunize more than 500 million people in the world
Largest product range available, against 20 infectious diseases
More than €1 million invested every day in R&D
Nearly €2 billion invested in the last 5 years in production infrastructures.
Headquarters: Lyon, France
14 production and/or R&D sites located in:
Marcy-l'Étoile and Val-de-Reuil, France
Swiftwater, Pennsylvania (Sanofi Pasteur's United States headquarters), Cambridge, Massachusetts and Canton, Massachusetts, Orlando, Florida and Rockville, Maryland, United States
Toronto, Ontario, Canada
Pilar, Buenos Aires Province, Argentina
Shenzhen, China
Hyderabad, India
Ocoyoacac, Mexico
Chachoengsao, Thailand
Neuville-sur-Saône, France
Dengvaxia - Sanofi's dengue vaccine approved in 11 countries
TheraCys - bladder cancer
ADACEL (Tdap) - diphtheria, tetanus and pertussis
DAPTACEL (DTaP) - diphtheria, tetanus and pertussis
Diphtheria and Tetanus Toxoids Adsorbed USP, diphtheria, tetanus and pertussis
Tetanus Toxoid Adsorbed - diphtheria, tetanus and pertussis
TriHIBit (DTaP/Hib Booster Use) - diphtheria, tetanus and pertussis and haemophilus influenzae type b
Tripedia (DTaP vaccine) - diphtheria, tetanus, pertussis
ActHIB - haemophilus influenzae type b
Fluzone, Influenza Virus Vaccine - influenza
Fluzone, Influenza Virus Vaccine, No Preservative - influenza
Fluzone, Influenza Virus Vaccine, No Preservative: Ped Dose - influenza
Menactra - meningococcal
Menomune-A/C/Y/W-135 - meningococcal
IPOL - Polio
Imogam Rabies-HT - rabies immune globulin
IMOVAX RABIES - rabies
DECAVAC - tetanus and diphtheria
Tetanus Toxoid Adsorbed - tetanus
Tetanus Toxoid For Booster Use Only - tetanus
JE-VAX - Japanese encephalitis virus
Typhim Vi - typhoid fever
YF-VAX - yellow fever
Tubersol - tuberculosis
In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. The Toronto Sanofi plant On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.
